Alpine Global Management, LLC Affimed N.V. Transaction History

Alpine Global Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $42,339 - $94,300	38,490 New	38,490 $48,000
Q3 2020 Nov 12, 2020	SELL	$3.26 - $4.73 $48,900 - $70,950	-15,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$1.58 - $4.63 $248,695 - $728,771	-157,402 Reduced 91.3%	15,000 $69,000
Q1 2020 Apr 09, 2020	SELL	$1.44 - $3.02 $39,133 - $82,071	-27,176 Reduced 13.62%	172,402 $272,000
Q4 2019 Jan 16, 2020	BUY	$2.25 - $3.07 $449,050 - $612,704	199,578 New	199,578 $547,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpine Global Management, LLC with notifications on news.